Transplantation, AutologousHematopoietic Stem Cell TransplantationTransplantation ConditioningTransplantation, HomologousWhole-Body IrradiationGraft vs Host DiseaseDisease-Free SurvivalHematologic NeoplasmsMyeloablative AgonistsStem Cell TransplantationUnrelated DonorsBone Marrow TransplantationPeripheral Blood Stem Cell TransplantationTransplantation ChimeraTissue DonorsHistocompatibility TestingLiver TransplantationTreatment OutcomeHistocompatibilityCord Blood Stem Cell TransplantationGraft SurvivalVidarabineHematopoietic Stem CellsGraft vs Tumor EffectRetrospective StudiesBusulfanRecurrenceSiblingsLeukemiaLeukemia, Myeloid, AcuteKidney TransplantationImmunosuppressive AgentsChimerismSurvival AnalysisHLA AntigensRemission InductionCell TransplantationGraft vs Leukemia EffectDonor SelectionSurvival RateGraft RejectionMyelodysplastic SyndromesTransplantation ImmunologyCombined Modality TherapyTime FactorsTransplantationHematologic DiseasesMultiple MyelomaHeart TransplantationDirected Tissue DonationHematopoiesisFollow-Up StudiesPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvivorsMycophenolic AcidLymphoma, Non-HodgkinCyclosporineLung TransplantationAcute DiseaseCyclophosphamideImmunosuppressionLiving DonorsT-LymphocytesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphocyte TransfusionAntilymphocyte SerumBone Marrow CellsAllograftsMinor Histocompatibility AntigensAnemia, AplasticRisk FactorsMucopolysaccharidosis IHepatic Veno-Occlusive DiseaseAntigens, CD34Organ TransplantationSalvage TherapyHematopoietic Stem Cell MobilizationCytomegalovirus InfectionsBlood Transfusion, AutologousAntineoplastic Combined Chemotherapy ProtocolsIslets of Langerhans Transplantation